Conceivably, 7HP349 therapy, which increases CD8+ Teff recruitment to the TME in cooperation with neutrophils in a CXCL12-dependent manner, could trigger efficient tumor infiltration by CD8+ Teffs and increase the percentage of cancer patients who experience a response to immunotherapy. Here, CXCL12 is linked to cancer.